Get App
Indoco Remedies > Company History > Pharmaceuticals > Company History of Indoco Remedies - BSE: 532612, NSE: INDOCO

Indoco Remedies

BSE: 532612|NSE: INDOCO|ISIN: INE873D01024|SECTOR: Pharmaceuticals
Feb 20, 15:47
5.7 (2.19%)
VOLUME 3,703
Feb 20, 15:55
7.5 (2.89%)
VOLUME 98,445
Company History - Indoco Remedies
In 1945, a Goan entrepreneur Mr. Govind Ramnath Kare, who was in the
 business of wholesale and retail trade of pharmaceuticals, started a
 firm which he named Indo Continental Trading Company. The principal
 business of this firm was to import pharmaceutical formulations from
 Europe and distribute them in Western India. However in 1947, after
 India became independent, the new Government in its bid to encourage
 indigenous manufacturing of medicines banned import of several
 formulations. Mr. G.R. Kare instead of being discouraged, decided to
 venture into manufacturing of pharmaceuticals. Accordingly, on 23rd
 August 1947, a week after India's independence, a new Company was
 founded with the intent to manufacture and sell pharmaceutical
 formulations. Thus Indo Continental Trading Company became Indoco
 Remedies Limited.
 The manufacturing operations were started in a small house in Thane
 near Mumbai. However in this early period, the Company suffered a
 severe set-back. After Indian independence, the Portuguese Government
 in Goa sealed the border between Goa and India and Mr. Kare was unable
 to travel to Mumbai very often. In 1963, two years after Goa's
 independence, Mr. Suresh Kare, son of Mr. G.R. Kare came to Mumbai
 and took over as Managing Director of the then sick unit. Under the
 stewardship of Mr. Suresh Kare, Indoco never looked back. From a
 meager turnover of Rs. 1 Million and a total employee strength of
 around 50 in 1969, the Company has grown by leaps and bounds. Indoco
 now has an estimated turnover of Rs. 1.81 Billion for the year
 2003-04 and is over 1750 employees strong.
 -Indoco Remedies enters into an Agency Agreement with SRU
 - Indoco Remedies mulls to enter US mkt.
 - Indoco Remedies secures US FDA approvals.
 - Board has proposed a dividend of 62.5%.
 - Mr. J. B. Salian has been appointed the Secretary of the Company.
 - Board has proposed a dividend of 65% .
 -  Board has recommended a dividend of Rs 5.00 per share.
 - IDMA Quality Excellence Awards 2008 - The Sterile Facility at Goa
 Plant II received the Gold Award and the Solid Dosage Forms and
 Externals Facility at Goa Plant I received the Silver Award.
 - First shipment of Diclofenac Ophthalmic solution shipped to USA
 against an approved ANDA. 
 - Board has decided to declare a final dividend of Rs 2.00 per equity
 - UK-MHRA approval for the Solid Oral Dosage forms at Baddi Plant.
 - Successfully faced Slovenia audit for the Sterile Facility at Goa
 Plant II for the Injections Area.
 - The Company has signed an agreement with Aspen Pharmacare, South
 Africa for supply of ophthalmic products.
 - Board has recommended a payment of divided of Rs. 7.00 per equity
 - Indoco Remedies teams up with ASPEN, South Africa by licensing out
 intellectual property (dossiers) for marketing its products in
 emerging markets covering 30 countries, including SA, Brazil, Mexico,
 Venezuela, Russia & Australia. 
 - Board has recommended a dividend of Rs. 8/- per equity share.
 - Indoco received the Silver Quality Excellence Award for Sterile
 Manufacturing Facility in Goa and Solid Dosages Facility in Baddi
 (Himachal\Pradesh) at IDMA's Golden Jubilee celebrations. 
 - Indoco Remed - Enters into a strategic business alliance with DSM
 Pharmaceutical Products (DPP) NV.
 - Mr. Sunil Joshi has been appointed as Company Secretary &
 Compliance Officer of the Company.
 - Indoco announced the signing of an agreement with DSM, a  9
 billion Company, for commercial cooperation for Active Pharmaceutical
 Ingredients (APIs). Indoco and DSM have formed a strategic alliance,
 wherein DSM shall be marketing and selling the APIs manufactured by
 -Company has splits its Face value of Shares from Rs 10 to Rs 2
 -Indoco Remedies has given the Bonus in the Ratio of 1:2
 -Indoco Remedies Ltd. has received the approval from United States
 Food & Drug Administration (USFDA) to manufacture and market
 GLIMEPIRIDE 1mg, 2mg & 4mg tablets.
 -Indoco Remedia Ltd. has recommended payment of dividend of Rs.1.10
 per equity share on the face value of Rs. 2/- each i.e. 55% for
 financial year 2012-13.
 -US-FDA approves Sterile (Plant II) and Solid Dosages (Plant III)
 facilities in Goa.
 -IDMA Best Patent Award for Tazarotene & Adapalene.
 -Indoco Remedies Ltd. has Certificate of Good Manufacturing Practice
 (GMP) Compliance of a Manufacturer.
 - Indoco wins IDMA Patent Appreciation Award for Betaxolol
 - Indoco acquires Piramal's Clinical Research Division
 -  Indoco acquires Manufacturing plant at Baddi
 -  Indoco Honoured with the IDMA Best Patent Award for Three
 International Patents
 - Indoco honoured with the 'Best Patent Award' by PHARMEXCIL in the
 Bulk Drugs / API category
Source : Dion Global Solutions Limited
Quick Links for Indoco Remedies
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of is prohibited.